Stock Price Quote

TTK HEALTHCARE LTD.

NSE : TTKHLTCAREBSE : 507747ISIN CODE : INE910C01018Industry : Pharmaceuticals & DrugsHouse : TTK
BSE1477.00-18.25 (-1.22 %)
PREV CLOSE ( ) 1495.25
OPEN PRICE ( ) 1503.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 45910
TODAY'S LOW / HIGH ( )1470.00 1503.00
52 WK LOW / HIGH ( )827.65 1575
NSE1485.40-8.7 (-0.58 %)
PREV CLOSE( ) 1494.10
OPEN PRICE ( ) 1494.50
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 7328
TODAY'S LOW / HIGH( ) 1470.00 1500.00
52 WK LOW / HIGH ( )828.1 1583.6
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1958
Management Info
T T Raghunathan - Chairman - Managing Director
Registered Office

Address No 6 , Cathedral Road, , ,
Chennai,
Tamil Nadu-600086

Phone 044-28116106-08

Email info@ttkhealthcare.com

Website www.ttkhealthcare.com

Registrars Details
Data Software Research Co Pvt Ltd
19 Pycroft Garden Road,Off Haddows Road,Nungambakkam,Chennai
Listing : BSE, NSE, MCX

NEWS

22Dec Ttk Healthcare informs about clarifica
With acknowledge receipt of communication L/SURV/ONL/PV/NP/2023-2024/497..
21Nov Ttk Healthcare informs about loss of s
Ttk Healthcare has informed that it enclosed Certificate under Reg 39(3)..
03Nov Ttk Healthcare submits unaudited finan
Ttk Healthcare has informed that it enclosed the Unaudited Financial Res..
17Aug TTK Healthcare informs about details o
Pursuant to Regulation 39(3) of SEBI (LODR) Regulations, 2015, TTK Healt..
26May TTK Healthcare informs about secretari
In accordance with SEBI Circular No. CIR/CFD/CMD1/27/2019 dated 8th Febr..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit128.956397.15
Gross Profit 177 616.370000000001
Operating Profit 212.4796.820000000001
Net Sales 1838.477251.1

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  28639.35 (0.55%)
M.Cap ( in Cr)60856.62
Bharat Parenterals (BSE)
peergroup  1147.65 (10.28%)
M.Cap ( in Cr)667.89
Astrazeneca Pharma I (BSE)
peergroup  5567.65 (1.95%)
M.Cap ( in Cr)13919.13
Neuland Laboratories (BSE)
peergroup  7063.75 (1.37%)
M.Cap ( in Cr)9062.71
Mankind Pharma (BSE)
peergroup  2097.55 (1.58%)
M.Cap ( in Cr)84025.43

Shareholding Pattern

PROMOTERS 74.56%
NON-INSTITUTION 20.45%
MUTUAL FUNDS/UTI 1.99%
FII 1.85%
FI/BANKS/INSURANCE 0.01%
GOVERNMENT 0%

About TTK Healthcare Ltd.

TTK Healthcare Ltd. was incorporated in the year 1958. Its today's share price is 1477. Its current market capitalisation stands at Rs 2087.05 Cr. In the latest quarter, company has reported Gross Sales of Rs. 7251.1 Cr and Total Income of Rs.7734.42 Cr. The company's management includes T T Mukund, S Kalyanaraman, V Ranganathan, N Ramesh Rajan, S Balasubramanian, Girish Rao, Vandana R Walvekar, K Shankaran, R K Tulshan, T T Raghunathan.

It is listed on the BSE with a BSE Code of 507747 , NSE with an NSE Symbol of TTKHLTCARE and ISIN of INE910C01018. It's Registered office is at No 6 , Cathedral Road, , Chennai-600086, Tamil Nadu. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Aiyar & Co, PKF Sridhar & Santhanam LLP, S Viswanathan, S Viswanathan LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.